Meeting
2019 ASCO Annual Meeting
Factors associated with osteonecrosis of the jaw in women with breast cancer receiving high-dose bisphosphonates to prevent breast cancer metastases as part of the SWOG 0307 trial.
Authors
Darya Kizub
Everett Clinic, Everett, WA
Darya Kizub , Jieling Miao , Mark M. Schubert , Alexander H. G. Paterson , Mark J. Clemons , Elizabeth Claire Dees , James N. Ingle , Carla Isadora Falkson , William E. Barlow , Gabriel N. Hortobagyi , Julie Gralow
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT00127205
Citation
J Clin Oncol 37, 2019 (suppl; abstr 552)
DOI
10.1200/JCO.2019.37.15_suppl.552
Abstract #
552
Poster Bd #
44
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: Comparison of toxicities and patient-stated preference for oral versus intravenous delivery.
First Author: Julie Gralow
Poster
2023 ASCO Annual Meeting
Multicenter, retrospective population-based study on the incidence of medication-related osteonecrosis of the jaw in patients with breast cancer with bone metastases.
First Author: Christine Brunner
Poster
2018 ASCO Annual Meeting
Overall survival in female Medicare beneficiaries with early stage breast cancer receiving bisphosphonates or denosumab.
First Author: Raul A Herrera Pena
Poster
2015 Genitourinary Cancers Symposium
Potential synergistic effects of bisphosphonates with sorafenib on renal cell carcinoma with bone metastases.
First Author: Ye Ding-Wei